0001477932-23-008963.txt : 20231205 0001477932-23-008963.hdr.sgml : 20231205 20231205080757 ACCESSION NUMBER: 0001477932-23-008963 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231205 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36833 FILM NUMBER: 231465250 BUSINESS ADDRESS: STREET 1: 1489 WEST WARM SPRINGS ROAD STREET 2: SUITE 110 CITY: HENDERSON STATE: NV ZIP: 89014 BUSINESS PHONE: 1 (646) 650-1351 MAIL ADDRESS: STREET 1: 1489 WEST WARM SPRINGS ROAD STREET 2: SUITE 110 CITY: HENDERSON STATE: NV ZIP: 89014 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 8-K 1 vnrx_8k.htm FORM 8-K vnrx_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 5, 2023

 

VolitionRx Limited

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36833

 

91-1949078

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

Identification Number)

 

1489 West Warm Springs Road, Suite 110

Henderson, Nevada 89014

(Address of principal executive offices and Zip Code)

 

+1 (646) 650-1351

(Registrant’s telephone number, including area code )

 

Not applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock,par value $0.001 per share

 

VNRX

 

NYSE American, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of  the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

Item 8.01. Other Events.

 

On December 5, 2023, VolitionRx Limited (the “Company”) issued a press release announcing the closing of an aggregate of Euro 5.0 million, or approximately $5.5 million U.S. dollars, in financing from Wallonie Entreprendre S.A. in Belgium. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number

 

Description

 

 

 

99.1

 

Press Release of VolitionRx Limited, dated December 5, 2023.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VOLITIONRX LIMITED

 

 

 

 

Date: December 5, 2023

By:

/s/ Cameron Reynolds

 

 

Cameron Reynolds

 

 

 

Chief Executive Officer & President

 

 

 

3

 

 EX-99.1 2 vnrx_ex991.htm PRESS RELEASE vnrx_ex991.htm

EXHIBIT 99.1

 

VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre

 

Henderson, Nevada, December 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A. (“WE”) in Belgium.

 

Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its clinical and regulatory program for Nu.Q® NETs, which it believes will aid the early diagnosis of diseases such as sepsis.

 

Volition is currently working with leading clinicians and researchers at centers of excellence worldwide to help facilitate the effective introduction of Nu.Q® NETs into clinical practice.

 

The Euro 5.0 million financing from WE consists of a Euro 2.5 million unsecured loan to Volition’s subsidiary, Belgian Volition SRL, and a Euro 2.5 million purchase of 3,205,431 shares of Volition’s restricted common stock at a purchase price of $0.8337 per share in a private placement transaction. The unsecured loan bears interest at a rate of approximately 8% per year and has a stated maturity date of December 31, 2028. Subject to certain conditions, the loan can be drawn down in three tranches at Belgian Volition’s election on or prior to June 30, 2025, with Euro 1.5 million available immediately, Euro 0.5 million available from June 1, 2024 and the final Euro 0.5 million available from March 1, 2025. 

 

Gaetan Michel, Chief Operating Officer of Volition, said: “We are enormously grateful to WE for this latest financing, and for the ongoing financial assistance we have received from agencies within Wallonia to date.”

 

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals. For more information about Volition’s Nu.Q® technology go to: www.volition.com

 

The shares of restricted common stock were issued by Volition to WE in a private placement in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations promulgated thereunder. The shares of common stock will not be registered under the Securities Act or any state securities laws and unless so registered may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities.

 

About Volition

 

Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

 

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also improve their quality of life.

 

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

 

 

 

 

 

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.

 

Media Enquiries:

 

Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620

 

Safe Harbor Statement

 

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the intended use of proceeds from the financing,  the effectiveness of Volition’s blood-based diagnostic, prognostic and disease monitoring tests, and Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

 

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.  Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

 

 

2

 

 EX-101.SCH 3 vnrx-20231205.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vnrx-20231205_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer EX-101.CAL 5 vnrx-20231205_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 vnrx-20231205_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 vnrx-20231205_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 05, 2023
Cover [Abstract]  
Entity Registrant Name VolitionRx Limited
Entity Central Index Key 0000093314
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Dec. 05, 2023
Entity File Number 001-36833
Entity Incorporation State Country Code DE
Entity Tax Identification Number 91-1949078
Entity Address Address Line 1 1489 West Warm Springs Road
Entity Address Address Line 2 Suite 110
Entity Address City Or Town Henderson
Entity Address State Or Province NV
Entity Address Postal Zip Code 89014
City Area Code 646
Local Phone Number 650-1351
Security 12b Title Common Stock,par value $0.001 per share
Trading Symbol VNRX
Security Exchange Name NYSEAMER
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
XML 9 vnrx_8k_htm.xml IDEA: XBRL DOCUMENT 0000093314 2023-12-05 2023-12-05 iso4217:USD shares iso4217:USD shares 0000093314 false 8-K 2023-12-05 VolitionRx Limited DE 001-36833 91-1949078 1489 West Warm Springs Road Suite 110 Henderson NV 89014 646 650-1351 false false false false Common Stock,par value $0.001 per share VNRX NYSEAMER false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://vnrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports vnrx-20231205.xsd vnrx-20231205_cal.xml vnrx-20231205_def.xml vnrx-20231205_lab.xml vnrx-20231205_pre.xml vnrx_8k.htm http://xbrl.sec.gov/dei/2023 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vnrx_8k.htm": { "nsprefix": "vnrx", "nsuri": "http://vnrx.com/20231205", "dts": { "schema": { "local": [ "vnrx-20231205.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "vnrx-20231205_cal.xml" ] }, "definitionLink": { "local": [ "vnrx-20231205_def.xml" ] }, "labelLink": { "local": [ "vnrx-20231205_lab.xml" ] }, "presentationLink": { "local": [ "vnrx-20231205_pre.xml" ] }, "inline": { "local": [ "vnrx_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://vnrx.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-12-05to2023-12-05", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-12-05to2023-12-05", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001477932-23-008963-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-008963-xbrl.zip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end